亚虹医药-U
(688176)
| 流通市值：24.59亿 | | | 总市值：37.73亿 |
| 流通股本：3.71亿 | | | 总股本：5.70亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 24,319,537.45 | 13,753,343.12 | 2,996,071.25 | 77,772.96 |
| 营业收入 | 24,319,537.45 | 13,753,343.12 | 2,996,071.25 | 77,772.96 |
| 二、营业总成本 | 117,128,087.84 | 447,147,582.54 | 296,713,781.81 | 206,880,387.42 |
| 营业成本 | 5,115,271.22 | 2,888,452.45 | 512,652.64 | 11,665.94 |
| 税金及附加 | 193,080.87 | 350,702.23 | 201,072.51 | 149,742.3 |
| 销售费用 | 32,638,884.7 | 34,420,005.17 | 16,618,160.77 | 8,008,453.85 |
| 管理费用 | 21,832,845.76 | 83,134,002.62 | 59,748,895.68 | 38,069,220.9 |
| 研发费用 | 68,099,878.3 | 364,591,785.25 | 246,139,715.41 | 176,904,016.76 |
| 财务费用 | -10,751,873.01 | -38,237,365.18 | -26,506,715.2 | -16,262,712.33 |
| 其中:利息费用 | 736,757.2 | 2,965,500.24 | 573,721.56 | 376,828.32 |
| 其中:利息收入 | 12,261,459.54 | 42,216,954.31 | 28,631,500.15 | 16,529,507.73 |
| 加:公允价值变动收益 | 2,386,259.17 | 19,584,509.52 | 13,811,937.76 | 12,693,483.85 |
| 加:投资收益 | 7,951,174.26 | 5,807,383.27 | 8,382,363.52 | 3,707,834.4 |
| 资产减值损失(新) | -429,726.42 | -39,007.35 | -49,189.3 | 848.14 |
| 信用减值损失(新) | -915,982.61 | -995,760.62 | -398,098.38 | -202,815.03 |
| 其他收益 | 503,764.77 | 5,033,980.12 | 4,840,869.53 | 4,696,461.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -83,313,061.22 | -404,003,134.48 | -267,129,827.43 | -185,906,801.46 |
| 加:营业外收入 | - | 2,576,500.01 | -1,000,000 | 500,000 |
| 减:营业外支出 | - | 76,366.18 | 26,366.18 | 26,338.28 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -83,313,061.22 | -401,503,000.65 | -268,156,193.61 | -185,433,139.74 |
| 减:所得税费用 | -343,675.93 | -668,011.96 | - | - |
| 六、净利润 | -82,969,385.29 | -400,834,988.69 | -268,156,193.61 | -185,433,139.74 |
| 持续经营净利润 | -82,969,385.29 | -400,834,988.69 | -268,156,193.61 | -185,433,139.74 |
| 归属于母公司股东的净利润 | -82,848,207.86 | -400,434,603.65 | -268,043,612.1 | -185,433,139.74 |
| 少数股东损益 | -121,177.43 | -400,385.04 | -112,581.51 | - |
| (一)基本每股收益 | -0.15 | -0.7 | -0.47 | -0.33 |
| (二)稀释每股收益 | -0.14 | -0.67 | -0.46 | -0.32 |
| 八、其他综合收益 | -1,115,257.61 | 2,100,690.64 | 1,363,641.29 | 1,958,305.92 |
| 归属于母公司股东的其他综合收益 | -1,069,400.13 | 2,063,622.14 | 1,351,147.67 | 1,958,305.92 |
| 九、综合收益总额 | -84,084,642.9 | -398,734,298.05 | -266,792,552.32 | -183,474,833.82 |
| 归属于母公司股东的综合收益总额 | -83,917,607.99 | -398,370,981.51 | -266,692,464.43 | -183,474,833.82 |
| 归属于少数股东的综合收益总额 | -167,034.91 | -363,316.54 | -100,087.89 | - |
| 公告日期 | 2024-04-30 | 2024-04-18 | 2023-10-31 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |